Targeting the Root Cause of Cystic Fibrosis

Author(s): Laura Trescott, Joshua Holcomb, Nicholas Spellmon, Cathy Mcleod, Leala Aljehane, Fei Sun, Chunying Li, Zhe Yang.

Journal Name: Current Drug Targets

Volume 16 , Issue 9 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Cystic Fibrosis (CF) is a serious genetic condition caused by CF transmembrane conductance regulator (CFTR) mutation. CF patients have shortened lifespan due to airway obstruction, infection, and end-stage lung failure. However, recent development in CF therapy suggests a brighter future for CF patients. Targeting specific CFTR mutations aims to potentiate the channel gating activity of impaired CFTR and restore protein trafficking to the plasma membrane. Gene therapy introduces correct CFTR gene into the affected airway epithelium leading to the functional expression of CFTR in CF patients. This review will sum up the current status in CF-cause targeting therapy.

Keywords: CFTR, chloride transporter, corrector, cystic fibrosis, gene therapy, potentiator.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 9
Year: 2015
Page: [937 - 944]
Pages: 8
DOI: 10.2174/1389450115999141030144247
Price: $58

Article Metrics

PDF: 49